TAK
Takeda Pharmaceutical Co Ltd ADR
NYSE: TAK · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$16.46
+0.97% today
Updated 2026-06-05
Market cap
$49.67B
P/E ratio
42.49
P/S ratio
0.01x
EPS (TTM)
$0.37
Dividend yield
4.21%
52W range
$13 – $19
Volume
3.1M
WallStSmart proprietary scores
57
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B5.0
Quality
C+4.0
Profitability
C6.3
Valuation
B4/9
Piotroski F-Score
Moderate
1.2
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$24.00
+45.81%
12-Month target
$10.30
-37.42%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z 1.18 — distress zone
- Thin margins at 4.26%
- Negative free cash flow $-26.01B
- P/E 42.49x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM | 2027 (E) |
|---|---|---|---|---|---|---|
| Revenue | $4.03T | $4.26T | $4.58T | $4.78T | $4.51T | $4850.0B |
| Net income | $317.02B | $144.07B | $107.93B | $203.33B | $-24.77B | — |
| EPS | — | — | — | — | $0.37 | $165.00 |
| Free cash flow | $343.47B | $235.61B | $856.39B | $808.70B | $-26.01B | — |
| Profit margin | 7.87% | 3.38% | 2.36% | 4.26% | 4.26% | — |
Peer comparison
Smart narrative
Takeda Pharmaceutical Co Ltd ADR trades at $16.46. representing a P/E of 42.49x trailing earnings. Our Smart Value Score of 57/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.18, it sits in the distress. TTM revenue stands at $4.51T. with profit margins at 4.26%.
Frequently asked questions
What is Takeda Pharmaceutical Co Ltd ADR's stock price?
Takeda Pharmaceutical Co Ltd ADR (TAK) trades at $16.46, on a P/E of 42.5x and a P/S of 0.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Takeda Pharmaceutical Co Ltd ADR overvalued?
Takeda Pharmaceutical Co Ltd ADR carries a Smart Value Score of 57/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of Takeda Pharmaceutical Co Ltd ADR (TAK)?
The 12-month analyst consensus target is $24.00, about 45.8% above the current $16.46. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of TAK by 2030?
Our research-backed model puts the 2030 base case at $22,373.69, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Takeda Pharmaceutical Co Ltd ADR's revenue?
Takeda Pharmaceutical Co Ltd ADR's trailing twelve-month revenue is $4.51T, and our model projects it reaching about $5.89T by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Takeda Pharmaceutical Co Ltd ADR's Altman Z-Score is 1.18, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.01x
ROE2.47%
Beta0.09
50D MA$16.89
200D MA$15.99
Shares out3.16B
Float3.16B
Short ratio—
Avg volume3.1M
Performance
1 week+0.00%
1 month-6.08%
3 months-12.21%
YTD+0.06%
1 year—
3 years—
5 years—